Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 1;107(10):2292-2294.
doi: 10.3324/haematol.2021.280395.

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?

Ashley Pinchinat  1 , Elizabeth Raetz  2
Affiliations
Comment

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?

Ashley Pinchinat et al. Haematologica. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Tasian SK, Silverman LB, Whitlock JA, et al. . Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022;107(10):2295-2303. - PMC - PubMed
    1. Rheingold SR, Ji L, Xu X, et al. . Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children’s Oncology Group (COG) study. J Clin Oncol. 2019;37(15_suppl):10008.
    1. Ko RH, Ji L, Barnette P, et al. . Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648-654. - PMC - PubMed
    1. Sun W, Malvar J, Sposto R, et al. . Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia & Lymphoma study. Leukemia. 2018;32(11):2316-2325. - PMC - PubMed
    1. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108. - PMC - PubMed

Publication types

MeSH terms